Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-part Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of Intranasal BPL-003 (5-Methoxy-N,N-dimethyltryptamine Benzoate) in Healthy Subjects

Next Previous
X
Search
Trial Profile

A Two-part Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of Intranasal BPL-003 (5-Methoxy-N,N-dimethyltryptamine Benzoate) in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 5 Methoxy N N Dimethyltryptamine (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions
  • Sponsors Beckley Psytech

    • Most Recent Events

    • 17 Apr 2024 According to an atai Life Sciences media release, the company announced the publication of the Phase 1 results of BPL-003, Beckley Psytech's novel synthetic intranasal benzoate salt formulation of 5-MeO-DMT, in The Journal of Psychopharmacology.
    • 17 Apr 2024 Results presented in the atai Life Sciences Media Release
    • 15 Sep 2023 Planned End Date changed from 1 Aug 2023 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top